Literature DB >> 15800304

A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process.

Steven M Shechter1, Cindy L Bryce, Oguzhan Alagoz, Jennifer E Kreke, James E Stahl, Andrew J Schaefer, Derek C Angus, Mark S Roberts.   

Abstract

BACKGROUND: The optimal allocation of scarce donor livers is a contentious health care issue requiring careful analysis. The objective of this article was to design a biologically based discrete-event simulation to test proposed changes in allocation policies.
METHODS: The authors used data from multiple sources to simulate end-stage liver disease and the complex allocation system. To validate the model, they compared simulation output with historical data.
RESULTS: Simulation outcomes were within 1% to 2% of actual results for measures such as new candidates, donated livers, and transplants by year. The model overestimated the yearly size of the waiting list by 5% in the last year of the simulation and the total number of pretransplant deaths by 10%.
CONCLUSION: The authors created a discrete-event simulation model that represents the biology of end-stage liver disease and the health care organization of transplantation in the United States.

Entities:  

Mesh:

Year:  2005        PMID: 15800304     DOI: 10.1177/0272989X04268956

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  25 in total

1.  Optimization of PSA screening policies: a comparison of the patient and societal perspectives.

Authors:  Jingyu Zhang; Brian T Denton; Hari Balasubramanian; Nilay D Shah; Brant A Inman
Journal:  Med Decis Making       Date:  2011-09-20       Impact factor: 2.583

2.  Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.

Authors:  Sumeyye Samur; Brian Kues; Turgay Ayer; Mark S Roberts; Fasiha Kanwal; Chin Hur; Drew Michael S Donnell; Raymond T Chung; Jagpreet Chhatwal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-17       Impact factor: 11.382

3.  A new organ transplantation location-allocation policy: a case study of Italy.

Authors:  Maria Elena Bruni; Domenico Conforti; Nicola Sicilia; Sandro Trotta
Journal:  Health Care Manag Sci       Date:  2006-05

4.  Declining liver graft quality threatens the future of liver transplantation in the United States.

Authors:  Eric S Orman; Maria E Mayorga; Stephanie B Wheeler; Rachel M Townsley; Hector H Toro-Diaz; Paul H Hayashi; A Sidney Barritt
Journal:  Liver Transpl       Date:  2015-08       Impact factor: 5.799

5.  Improving outcomes in state AIDS drug assistance programs.

Authors:  Benjamin P Linas; Elena Losina; Annette Rockwell; Rochelle P Walensky; Kevin Cranston; Kenneth A Freedberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

6.  A data-integrated simulation model to evaluate nurse-patient assignments.

Authors:  Durai Sundaramoorthi; Victoria C P Chen; Jay M Rosenberger; Seoung Bum Kim; Deborah F Buckley-Behan
Journal:  Health Care Manag Sci       Date:  2009-09

7.  Accept/decline decision module for the liver simulated allocation model.

Authors:  Sang-Phil Kim; Diwakar Gupta; Ajay K Israni; Bertram L Kasiske
Journal:  Health Care Manag Sci       Date:  2014-08-30

8.  D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation.

Authors:  Jeffrey B Halldorson; Robert L Carithers; Renuka Bhattacharya; Ramasamy Bakthavatsalam; Iris W Liou; Andre A Dick; Jorge D Reyes; James D Perkins
Journal:  World J Transplant       Date:  2014-09-24

9.  Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.

Authors:  Jagpreet Chhatwal; Sumeyye Samur; Emily D Bethea; Turgay Ayer; Fasiha Kanwal; Chin Hur; Mark S Roberts; Norah Terrault; Raymond T Chung
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

10.  Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.

Authors:  Mark Roberts; Louise B Russell; A David Paltiel; Michael Chambers; Phil McEwan; Murray Krahn
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.